Jeeyun Lee
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (74)
The activities of bispecific antibodies against VEGF and PD-1 have reinvigorated interest in dual VEGF and PD-1 targeting across solid tumors. However, the tumor and immune features influencing tumor response remain largely unknown. We conducted a single-arm phase II trial evaluating dual VEGFR2 and PD-1 targeting with ramucirumab and pembrolizumab in pretreated PD-L1 + gastric cancer. Twenty-six patients were enrolled between June 2021 and May 2023. Nine patients received anti–PD-1 therapy before trial enrollment. There were no complete responses, but six patients had a partial response, for an objective response rate of 23%. The median progression-free survival was 2.7 months, and the median overall survival was 10.9 months. Grade ≥3 treatment-related adverse events occurred in 39% of patients. Digital spatial profiling of serial primary tumor biopsies revealed distinct tumor microenvironment phenotypes between responders and nonresponders. Responders were characterized by higher baseline tumoral VEGF signaling, baseline enrichment in antigen processing and presentation in the immune compartment, shorter distances between tumor and immune cell populations, and greater on-treatment vascular normalization coupled to cytotoxic T-cell infiltration. Nonresponders had greater baseline hypoxia and platelet-derived growth factor scores, significantly upregulated TGFβ in immune cell regions, and greater distances between tumor and immune cells and immune cells and vessels. Paired peripheral blood mass cytometry revealed lower proportions of myeloid-derived suppressor cells in responders. Together, these data highlight on-treatment remodeling under the therapeutic pressure of dual VEGF and PD-1 blockade and suggest features associated with the durable benefit seen in a subset of patients.
Year:
2026
Supplementary Figure S7. Graphical summary of findings highlighting major differences between responder and non-responder patients in a phase II trial of ramucirumab plus pembrolizumab in advanced PD-L1+ gastric cancer.
Year:
2026
Serial plasma ctDNA in an individual patient demonstrating pre-treatment genomic heterogeneity and selection for resistant clones. Plasma ctDNA at diagnosis revealed ERBB2 amplification in a patient with HER2+ EG cancer, as well as numerous pre-existing resistance mechanisms including EGFR amplification, PIK3CA amplification, and an FGFR3-TACC3 fusion that was not identified on tumor sequencing (Figure 2b).
Year:
2025
Baseline biopsies from a patient demonstrating significant intra-patient heterogeneity with diffusely HER2+ and PD-L1– primary tumor and HER2– but PD-L1 CPS 100 retroperitoneal lymph node with neuroendocrine differentiation.
Year:
2025
Survival and response in patients receiving trastuzumab/chemotherapy + PD-1 inhibition on- or off-protocol (n=66). a, Progression-free survival and objective response rate by cohort. b, Overall survival by cohort.
Year:
2025
Identifying intratumor clonal selection and associated resistance mechanisms. a, Inferred tumor clones paired pre-treatment and post-cycle 2 CAPOX + trastuzumab scRNA-seq demonstrates rapid clearance of highly ERBB2 expression (red) clones, while many lower expressing clones persisted and even expanded. Contraction at the on-treatment timepoint reflects their RECIST response at their initial follow up imaging timepoint, demonstrating that patient 3, who had the highest ERBB2 expression, had the deepest and most durable response. b, Pre- and on-treatment size and fold-change of clones identified in pane a ordered by pre-treatment ERBB2 expression. Clonal expansion was most commonly seen in clones with low ERBB2 expression and was associated with a resistance program derived by GeneVector. c, MT1H, MT1E, MT2A, and MSMB expression were significantly higher in clones expanding despite CAPOX + trastuzumab (TC) versus both contracting clones after TC as well as expanding clones after CAPOX (C) only, suggesting association with therapeutic resistance. d, The resistance program strongly correlated with the CAPOX+trastuzumab clones, and poorly with CAPOX-treated clones, as intended.
Year:
2025
PIK3CD S367L demonstrate increased phosphorylation of AKT. Upon progression, 1 patient developed a PIK3CD S367L mutation (location indicated in gene map), a variant of undetermined significance in the carboxy terminal C2 domain. Above, western blot demonstrating pAKT expression in 3T3 cells stably expressing p110δ WT or mutations at p110d E1021K, L806M, S367L, R894Q, G971E, or R338W relative to non-transformed parental 3T3 cells, which do not express p110δ. Below, lollipop plot of PIK3CD.
Year:
2025
HER2 heterogeneity and RTK alterations are more frequent among patients with shorter PFS. HER2 testing and tissue/plasma ctDNA NGS upon progression demonstrate that 8 of 16 (50%) of patients had HER2 negative tumors post-treatment, and 2 ERBB2 amplified tumors pre-treatment were non-amplified post-treatment. Additionally, frequent alterations in PI3K, cell cycle proteins, Ras-Raf, EGFR, FGFR1/2, and MET were found upon progression, and potentially associated with treatment resistance.
Year:
2025
Lesions without pre-treatment ERBB2 amplification appear less likely to respond to pembrolizumab and trastuzumab induction. Lesion-level CT response after 1 dose of pembrolizumab and trastuzumab among patients with baseline tumor-matched ctDNA color-coded according to pre-treatment a, ctDNA ERBB2 amplification status and b, tissue WES ERBB2 amplification status.
Year:
2025
Background Claudin 18.2 (CLDN18.2) is a tight junction protein retained in malignant transformation of gastric cancer (GC) and is a promising therapeutic target. Despite the clinical benefit of zolbetuximab in CLDN18.2-positive tumors, the dynamic expression of CLDN18.2 during chemoimmunotherapy and its implications in the tumor microenvironment (TME) remain poorly understood. Methods In a prospective single-arm phase II trial, we evaluated serial tumor biopsies from patients with advanced GC receiving first-line chemotherapy (capecitabine/oxaliplatin) with sequential pembrolizumab. CLDN18.2 expression was assessed by immunohistochemistry, and integrated molecular analyses—including whole transcriptome, whole exome, and single-cell RNA sequencing—were performed to explore TME alterations and molecular correlates. Results Among 57 patients, 40.4% were CLDN18.2-positive at baseline. CLDN18.2 positivity was associated with diffuse-type histology, higher programmed death-ligand 1 (PD-L1) combined positive scores, and an immune-inflamed, stroma-rich TME characterized by enhanced T cell infiltration, transforming growth factor-β signaling, and matrix remodeling. Gene set enrichment analyses revealed immune activation and stromal remodeling in CLDN18.2-positive tumors. Single-cell analysis showed increased regulatory T cells and galectin-3-CD44 signaling in CLDN18.2-positive tumors. After one cycle of chemotherapy, CLDN18.2 expression was lost in 40% of initially positive tumors, while 10% of initially negative tumors gained expression—particularly in fibrotic TMEs. Survival outcomes were not significantly different between CLDN18.2-positive and CLDN18.2-negative groups; however, patients negative for both CLDN18.2 and PD-L1 showed poorer prognosis. Conclusions CLDN18.2 expression is dynamically regulated during chemoimmunotherapy and is associated with a distinct immunosuppressive and fibrotic TME. These findings highlight the importance of repeated biomarker assessment and suggest potential combinatorial therapeutic strategies targeting both epithelial and stromal compartments in GC. Trial registration number NCT04249739 .
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (28)
Byung-Hoon Min
Professor
Samsung Medical Center
Ryan Park
Assistant Professor
The University of Texas MD Anderson Cancer Center
Samuel Klempner
Associate Professor
Massachusetts General Hospital
Hyuk Lee
Sungkyunkwan University School of Medicine
Tiago Biachi de Castria
Associate Professor
University of South Florida
Kum-Hee Yun
Yonsei University College of Medicine
Inkyung Jung
Yonsei University College of Medicine
David Drew
Assistant Professor of Medicine
Massachusetts General Hospital
Sandra Ryeom
Associate Professor/Associate Dean
Columbia University Irving Medical Center
Young Han Lee
Yonsei University College of Medicine
Soomin Ahn
assistant professor
Samsung Medical Center
Seung Tae Kim
Sungkyunkwan University School of Medicine
Taha Merghoub
Deputy Director, Meyer Cancer Center
Weill Cornell Medicine
Tae Jun Kim
Sungkyunkwan University School of Medicine
Hyo Song Kim
Yonsei University College of Medicine
Sohrab Shah
Professor
Memorial Sloan Kettering Cancer Center
Hyang Joo Ryu
Yonsei University College of Medicine
Matthew Strickland
Harvard University
Umeshkumar Bhanot
Sloan Kettering Institute
Steven Maron
Assistant Attending
Memorial Sloan Kettering Cancer Center
Wooyeol Baek
Assistant professor
Severance Hospital
Harris Wang
Professor
Columbia University
Jeremy Davis
Professor and Chief, Division of Surgical Oncology
University of Maryland School of Medicine
Hong In Yoon
Yonsei University College of Medicine
Kyoung Mee Kim
Sungkyunkwan University
Jason S. Lewis
Weill Cornell Medical College
Woong-Yang Park
Professor
Sungkyunkwan University
Won Ki Kang
Professor
Sung Kyun Kwan University School of Medicine at Samsung Medical Center Cancer Center
Make your next move.
Prepare your application
Review drafts before you send them.